ERBB2 and non-small cell lung carcinoma: Additional therapeutic directions include HER2-directed therapies in ERBB2-mutant NSCLC (trastuzumab deruxtecan, poziotinib in development) and NTRK inhibitors (entrectinib, larotrectinib) for patients with rare fusions [57].